Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 249204, 12 pages
http://dx.doi.org/10.1155/2014/249204
Clinical Study

Effects of Marine Phospholipids Extract on the Lipid Levels of Metastatic and Nonmetastatic Prostate Cancer Patients

1Department of Lipids & Liposomes, Tumor Biology Center, Breisacher Straße 117, 79106 Freiburg, Germany
2Hermann Staudinger Graduate School, the University of Freiburg, Hebelstraße 27, 79104 Freiburg, Germany
3Pharmacy Department, University Hospital Heidelberg, Im Neuenheimer Feld 670, 69126 Heidelberg, Germany
4Loretto Hospital, Mercystraße 6-14, 79100 Freiburg, Germany
5Urological practice U3, Bertoldstraße 45, 79098 Freiburg, Germany
6PgXpertise, Bahnhofstraße 8, 79288 Gottenheim, Germany
7Center for Cancer Medicine, Breisacher Straße 84 B, 79110 Freiburg, Germany
8Department of Clinical Research, Tumor Biology Center, Breisacher Straße 117, 79106 Freiburg, Germany

Received 4 March 2014; Revised 16 May 2014; Accepted 9 June 2014; Published 13 August 2014

Academic Editor: Emanuele Boselli

Copyright © 2014 Daniela Küllenberg de Gaudry et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

High intake of omega-3 fatty acids (n-3 FAs) from fish has shown to reduce metastatic progression of prostate cancer. This clinical trial investigated the influence of high n-3 FA intake (marine phospholipids, MPL) on the FA composition of blood lipids, lysophosphatidylcholine (LPC), and on lipoproteins in prostate cancer patients and elderly men without prostate cancer. MPL supplementation resulted in a significant increase of n-3 FAs (eicosapentaenoic and docosahexaenoic acid) in blood lipids, while arachidonic acid (n-6 FA) decreased significantly. Low density lipoprotein (LDL) and high density lipoprotein (HDL) increased significantly, but the LDL increase was observed only in subjects with an inactive tumour. Similarly, LPC plasma concentration increased significantly only in patients without tumour. The missing increase of LDL and LPC after MPL supplementation in patients with actively growing (metastasizing) prostate cancer suggests that tumour cells have an elevated demand for LDL and LPC. Due to the MPL-induced increase of n-3 FAs in these blood lipids, it can be assumed that especially actively growing and metastasizing prostate cancer cells are provided with elevated amounts of these antimetastatic n-3 FAs. A hypothetic model explaining the lower incidence of metastatic progression in prostate cancer patients with high fish consumption is presented.